Efficacy of front-line treatment for hormone receptor-positive HER2-negative metastatic breast cancer with germline BRCA1/2 mutation.

MLA

Frenel, J. S., et al. “Efficacy of Front-Line Treatment for Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer with Germline BRCA1/2 Mutation.” British Journal of Cancer, vol. 128, no. 11, June 2023, pp. 2072–80. EBSCOhost, https://doi.org/10.1038/s41416-023-02248-4.

APA

Frenel, J.-S., Lusque, A., Delaloge, S., Ferrero, J.-M., Bachelot, T., Desmoulins, I., Levy, C., Eymard, J.-C., Gonçalves, A., Patsouris, A., Reynier, M. A. M., Thery, M. J.-C., Petit, T., Cabel, L., Uwer, L., Debled, M., Chevrot, M., Mailliez, A., Jacot, W., & de La Motte Rouge, T. (2023). Efficacy of front-line treatment for hormone receptor-positive HER2-negative metastatic breast cancer with germline BRCA1/2 mutation. British Journal of Cancer, 128(11), 2072–2080. https://doi.org/10.1038/s41416-023-02248-4

Chicago

Frenel, J-S, A Lusque, S Delaloge, J-M Ferrero, T Bachelot, I Desmoulins, C Levy, et al. 2023. “Efficacy of Front-Line Treatment for Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer with Germline BRCA1/2 Mutation.” British Journal of Cancer 128 (11): 2072–80. doi:10.1038/s41416-023-02248-4.